The purpose of this plan is building an inactive monovalent vaccine for RA serotype 2. The preliminary potency and safety assessments of trial vaccines on mule ducks have been completed, and the field trials are also under proceeding. This year, the trial vaccines will be readjusted and proven according to the results of potency and safety tests, and the estimation of stability of trial vaccines and field trials will be finished. Finally, the vaccine will be registered and commercialized.